Status:
COMPLETED
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Pain
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the safety and tolerability of AZD2066 using multiple escalating dose panels. There will be separate panels for young healthy volunteers and elderly healthy...
Eligibility Criteria
Inclusion
- Provision of signed informed consent
- Clinically normal physical findings and laboratory values as judged by the investigator and a normal resting ECG.
Exclusion
- History of somatic disease/condition, which may interfere with the objectives of the study, as judged by the investigator.
- History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder.
- Intake of medicine (except occasional paracetamol or nasal spray) within first 2 weeks before first administration of study drug.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00684502
Start Date
January 1 2008
End Date
November 1 2008
Last Update
December 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden